UTHR News and Press, United Therapeutics Corporation From 11/01/23

2023-11-01 04:17:37 ET More on United Therapeutics United Therapeutics Shifts Focus To Tyvaso DPI Amid Generic Threat United Therapeutics: Fundamental, Technical Analyses Justify A Buy Decision United Therapeutics Q3 2023 Earnings Preview United Therapeutics ...

2023-10-31 12:39:29 ET More on United Therapeutics United Therapeutics Shifts Focus To Tyvaso DPI Amidst Generic Threat United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth M...

Up to 60,000 patients in the United States may have PPF, with only one approved therapy available United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that the first patient has enrolled in the registration-phase TETON PPF study, whi...

United Therapeutics Corporation (Nasdaq: UTHR ), a public benefit corporation, announced today that Patrick Poisson , Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the UBS Biopharma Co...

2023-10-31 02:17:12 ET Summary I will recap the eleven partnership deals MannKind has been involved in over its operation as a corporation. I will share my opinion as it relates to the current status of these eleven partnerships. I will discuss why it is my opinion that MannKi...

2023-10-30 06:33:26 ET More on United Therapeutics United Therapeutics Shifts Focus To Tyvaso DPI Amidst Generic Threat United Therapeutics: Both Fundamental And Technical Analyses Justify A Buy Decision United Therapeutics: Eyeing A Re-Rating To 12-13x P/E, Growth M...

United Therapeutics Corporation (Nasdaq: UTHR ) and Miromatrix Medical Inc. (Nasdaq: MIRO ) announced today a definitive agreement for United Therapeutics to acquire Miromatrix. Miromatrix is a life sciences company focused on the development of bioengineered organs composed of human ...

United Therapeutics Corporation (Nasdaq: UTHR ), announced today that it will report its third quarter 2023 financial results before the market opens on Wednesday, November 1, 2023. United Therapeutics will host a public webcast Wednesday, November 1, 2023, at 9:00 a.m. Eastern Time. The ...

2023-10-23 03:35:36 ET Summary United Therapeutics' strategic pivot to Tyvaso DPI aims to thwart generic competition through enhanced efficacy and patient compliance. Robust liquidity and operational cash flow; low likelihood of external financing required in the near term. In...

2023-10-22 12:25:39 ET Summary United Therapeutics Corporation is in a long-term uptrend, reaching a new all-time high, indicating strong demand for the stock. The company has a competitive advantage with a diverse and unique product portfolio, driving revenue and profit growth. ...